Literature DB >> 29357795

Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy.

Joanna K Chang1, Allison Leso2, Gehad M Subaiea1,3, Asma Lahouel4, Anwar Masoud1,5, Foqia Mushtaq1, Reem Deeb1,6, Aseel Eid2, Miriam Dash2, Syed W Bihaqi6, Nasser H Zawia1,2,6.   

Abstract

BACKGROUND: Tangles are deposits of hyperphosphorylated tau, which are found in multiple neurodegenerative disorders that are referred to as tauopathies, of which Alzheimer's disease (AD) is the most common. Tauopathies are clinically characterized by dementia and share common cortical lesions composed of aggregates of the protein tau.
OBJECTIVE: In this study, we explored the therapeutic potential of tolfenamic acid (TA), in modifying disease processes in a transgenic animal model that carries the human tau gene (hTau).
METHODS: Behavioral tests, Western blotting and Immunohistochemical analysis were used to demonstrate the efficacy of TA.
RESULTS: Treatment of TA improved improving spatial learning deficits and memory impairments in young and aged hTau mice. Western blot analysis of the hTau protein revealed reductions in total tau as well as in sitespecific hyperphosphorylation of tau in response to TA administration. Immunohistochemical analysis for phosphorylated tau protein revealed reduced staining in the frontal cortex, hippocampus, and striatum in animals treated with TA.
CONCLUSION: TA holds the potential as a disease-modifying agent for the treatment of tauopathies including AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's disease; dementia; hTau mouse model; microtubule-associated protein Tau (MAPT); tauopathy; tolfenamic acid.

Mesh:

Substances:

Year:  2018        PMID: 29357795      PMCID: PMC7092365          DOI: 10.2174/1567205015666180119104036

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  28 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies.

Authors:  G Santpere; M Nieto; B Puig; I Ferrer
Journal:  Neurosci Lett       Date:  2005-12-27       Impact factor: 3.046

3.  Alzheimer's disease. Tangle disentanglement.

Authors:  K Beyreuther; C L Masters
Journal:  Nature       Date:  1996-10-10       Impact factor: 49.962

Review 4.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

Review 5.  Recent developments in tau-based therapeutics for neurodegenerative diseases.

Authors:  Miguel Medina
Journal:  Recent Pat CNS Drug Discov       Date:  2011-01

6.  Tolfenamic acid interrupts the de novo synthesis of the β-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway.

Authors:  L I Adwan; R Basha; M Abdelrahim; G M Subaiea; N H Zawia
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

7.  Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice--a longitudinal study.

Authors:  Matthew Phillips; Erik Boman; Hanna Osterman; David Willhite; Matthias Laska
Journal:  PLoS One       Date:  2011-05-05       Impact factor: 3.240

8.  The use of combination therapies in the acute management of migraine.

Authors:  Abouch Valenty Krymchantowski
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

9.  MAP2 and tau bind longitudinally along the outer ridges of microtubule protofilaments.

Authors:  Jawdat Al-Bassam; Rachel S Ozer; Daniel Safer; Shelley Halpain; Ronald A Milligan
Journal:  J Cell Biol       Date:  2002-06-24       Impact factor: 10.539

Review 10.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

View more
  7 in total

1.  Loss in efficacy measures of tolfenamic acid in a tau knock-out model: Relevance to Alzheimer's disease.

Authors:  Allison Leso; Syed W Bihaqi; Anwar Masoud; Joanna K Chang; Asma Lahouel; Nasser Zawia
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-26

Review 2.  Therapeutic strategies for tauopathies and drug repurposing as a potential approach.

Authors:  Majedul Islam; Fengyun Shen; Deepika Regmi; Deguo Du
Journal:  Biochem Pharmacol       Date:  2022-02-24       Impact factor: 6.100

3.  Machine learning prediction of incidence of Alzheimer's disease using large-scale administrative health data.

Authors:  Ji Hwan Park; Han Eol Cho; Jong Hun Kim; Melanie M Wall; Yaakov Stern; Hyunsun Lim; Shinjae Yoo; Hyoung Seop Kim; Jiook Cha
Journal:  NPJ Digit Med       Date:  2020-03-26

4.  Protective effect of hydrogen sulfide on oxidative stress-induced neurodegenerative diseases.

Authors:  Rubaiya Tabassum; Na Young Jeong; Junyang Jung
Journal:  Neural Regen Res       Date:  2020-02       Impact factor: 5.135

5.  Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations.

Authors:  Serena J Aleo; Valentina Del Dotto; Mario Fogazza; Alessandra Maresca; Tiziana Lodi; Paola Goffrini; Anna Ghelli; Michela Rugolo; Valerio Carelli; Enrico Baruffini; Claudia Zanna
Journal:  Hum Mol Genet       Date:  2021-01-21       Impact factor: 6.150

Review 6.  Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration.

Authors:  Marcello Giunta; Eino Solje; Fabrizio Gardoni; Barbara Borroni; Alberto Benussi
Journal:  J Exp Pharmacol       Date:  2021-03-24

Review 7.  Fenamates as Potential Therapeutics for Neurodegenerative Disorders.

Authors:  Jaunetta Hill; Nasser H Zawia
Journal:  Cells       Date:  2021-03-22       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.